Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT05718375

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Curacle Co., Ltd. (from the registry)
Registry
  • NCT NCT05718375
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05718375. Randomized; triple masking; primary purpose treatment. Start 2023-02-14 (actual); primary completion 2025-11-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria
Condition
Diabetic Nephropathies
Intervention (Drug)
CU01-1001
Intervention (Drug)
Placebo
Lead sponsor
Curacle Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05718375
Content hash
45c89abb9ef466e0e90ed64fe94f5b0109cf257c8f79f670dc3ca235cc94ff37